Serge Saxonov's guest appearances

Serge Saxonov

Change Wave

Mendelspod Podcast

Danny In The Valley

The Long Run with Luke Timmerman

Mara Aspinall

Carolyn Bertozzi

Bonnie Anderson

Pearl Huang

Emily Leproust

Christian Henry

Ethan Perlstein

John Ioannidis

George Church

Brad Gray

Aubrey de Grey

Naveen Jain

Jeff Bezos

Rob Knight

Jordan Fisher

OwlTail

The Sunday Times’ tech correspondent Danny Fortson brings on Serge Saxonov, founder of 10x Genomics, to talk about the end of normalcy (3:00), his high-end espresso machine for biology (4:20), delivering on the promise of genomics (6:20), how 10x is contributing to the coronavirus vaccine race (8:00), why a vaccine is theoretically achievable (10:15), the global shift to Covid research (13:15), leaving the Soviet Union and landing in New York (15:30), starting 23andMe (19:20), starting 10x (22:00), why it was hard to raise money (23:25), luring Softbank as an investor (25:55), 10x's footprint (26:50), the importance of resolution (28:10), and his worst day of work (32:00) Hosted on Acast. See acast.com/privacy for more information.

The Sunday Times’ tech correspondent Danny Fortson brings on Serge Saxonov, founder of 10x Genomics, to talk about the end of normalcy (3:00), his high-end espresso machine for biology (4:20), delivering on the promise of genomics (6:20), how 10x is contributing to the coronavirus vaccine race (8:00), why a vaccine is theoretically achievable (10:15), the global shift to Covid research (13:15), leaving the Soviet Union and landing in New York (15:30), starting 23andMe (19:20), starting 10x (22:00), why it was hard to raise money (23:25), luring Softbank as an investor (25:55), 10x's footprint (26:50), the importance of resolution (28:10), and his worst day of work (32:00) Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer nofollow" target="_blank">acast.com/privacy</a> for more information.

10x Genomics’ Serge Saxonov: "Never has so much brainpower been focussed on one problem"

Serge Saxonov co-founded 10x Genomics in 2012 and has served as the CEO since its inception. He has defined the company's vision and strategy, contributed to core inventions, and led 10x through multiple phases of rapid growth. 10x Genomics is a leading company in the field of genomics. The company was founded on the vision that this century will bring unprecedented advances in biomedicine to transform the way we understand and treat diseases leading to dramatic improvements in human health. In 2016, he was honored as one of Goldman Sachs 100 Most Intriguing Entrepreneurs of the Year. Prior to 10x Genomics, Serge was Vice President of Applications at QuantaLife, where he was responsible for building content, driving new applications, and identifying key diagnostics opportunities for the core ddPCR technology. Before QuantaLife, Serge was the first employee at 23andme. As Founding Architect and Director of R&amp;D, he defined the initial conception of the product, recruited a lot of the earlier team and built many key elements of the technology. Serge received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics and biology from Harvard College.

Serge Saxonov co-founded 10x Genomics in 2012 and has served as the CEO since its inception. He has defined the company's vision and strategy, contributed to core inventions, and led 10x through multiple phases of rapid growth. 10x Genomics is a leading company in the field of genomics. The company was founded on the vision that this century will bring unprecedented advances in biomedicine to transform the way we understand and treat diseases leading to dramatic improvements in human health. In 2016, he was honored as one of Goldman Sachs 100 Most Intriguing Entrepreneurs of the Year. Prior to 10x Genomics, Serge was Vice President of Applications at QuantaLife, where he was responsible for building content, driving new applications, and identifying key diagnostics opportunities for the core ddPCR technology. Before QuantaLife, Serge was the first employee at 23andme. As Founding Architect and Director of R&amp;D, he defined the initial conception of the product, recruited a lot of the earlier team and built many key elements of the technology. Serge received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics and biology from Harvard College.

10x Genomics: Serge Saxonov

Serge Saxonov on the single-cell analysis revolution.

Ep40: Serge Saxonov

When 10X Genomics launched their GemCode sequencing instrument at last year’s AGBT conference, what they offered seemed too good to be true.  10X was promising researchers a machine that could generate long reads using Illumina’s short read technology at a price lower than what PacBio could offer with their “real” long read instruments.  A year earlier, Illumina had announced they were buying Moleculo, a company that promised to offer long read data out of the short reads.  But good data with the Moleculo platform failed to materialize.

How Good are Linked Reads? Serge Saxonov, 10X Genomics